Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Capital International Investors, a division of Capital Research and Management Company and its investment management affiliates, reports amended beneficial ownership of common stock of Rapport Therapeutics, Inc..
CII is deemed to beneficially own 2,921,958 shares of Rapport Therapeutics common stock, representing 6.1% of the class, based on 47,826,929 shares believed to be outstanding. CII reports sole voting and sole dispositive power over 2,921,958 shares and no shared voting or dispositive power. The filing identifies SMALLCAP World Fund, Inc. as a person with rights to receive dividends or sale proceeds related to these securities.
Rapport Therapeutics, a clinical-stage biotech focused on precision small molecules for neurological and psychiatric disorders, reported a net loss of $56,615 (in thousands) for the three months ended June 30, 2026, and $76,472 (in thousands) for the six-month period. Operating expenses rose sharply, with research and development at $51,414 (in thousands) for the quarter as the company advanced its lead AMPA receptor negative allosteric modulator, RAP-219, and other programs.
Collaboration revenue of $20,000 (in thousands) in the first half of 2026 came entirely from an upfront payment under a license agreement granting Tenacia Biotechnology rights to RAP-219 in mainland China, Hong Kong, Macau and Taiwan. Cash, cash equivalents and short-term investments totaled $436.1 million as of June 30, 2026, which management expects will fund operating and capital needs for at least 12 months from the financial statement issuance date; the company nonetheless anticipates continued losses and the need for additional financing over time.
Rapport Therapeutics reported second quarter 2026 results and detailed progress across its precision neuroscience pipeline. The company recorded a net loss of $56.6 million, driven mainly by higher R&D expenses of $51.4 million and SG&A expenses of $9.4 million as clinical programs expanded.
Cash, cash equivalents and short-term investments totaled $436.1 million as of June 30, 2026, which the company expects will fund operations into the second half of 2029. Net cash used in operating activities was $41.5 million in the quarter.
Pivotal development of lead asset RAP-219 advanced, with Phase 3 FOCUS 1 and FOCUS 2 trials in focal onset seizures enrolling and an open-label safety study underway. Follow-up Phase 2a data showed median reductions of 80%–68% in long episodes and 90%–59% in clinical seizures. The company also highlighted a Phase 2 bipolar mania trial with topline data expected in October 2026, preparation for a Phase 3 trial in primary generalized tonic-clonic seizures in 2027, a long-acting injectable formulation moving toward Phase 1 in 2027, and continued IND-enabling work on RAP-641 for chronic pain and migraine.
Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported selling a total of 2,210 shares of common stock on July 27, 2026, in two transactions, including 2,203 shares at a weighted average price of $42.1070 (with individual trades between $41.66 and $42.50) and 7 shares at $42.7350 per share, pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
Separate from these sales, 81,729 shares are held by The Ceesay Family Irrevocable Trust and 20,729 shares by The Dorothy Ceesay Irrevocable Trust; Ceesay disclaims beneficial ownership of these trust-held shares except to the extent of any pecuniary interest.
Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported open-market sales of 8,210 shares of common stock on July 14, 2026, in two transactions at weighted-average prices of $40.57 and $39.72, executed under Rule 10b5-1 trading plans adopted on March 27, 2026. Following these sales, he holds 539,817 shares directly. Additional shares are held in two irrevocable trusts (20,729 and 81,729 shares), for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Rapport Therapeutics Chief Operating Officer Cheryl Gault reported open-market sales totaling 10,000 shares of common stock on June 30, 2026. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan at weighted average prices between about $40 and $43 per share.
Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported open-market sales of common stock under pre-arranged Rule 10b5-1 trading plans adopted on March 27, 2026. He sold 8,220 shares on June 29, 2026 in two transactions at weighted average prices of $39.77 and $40.34 per share.
Following these sales, Ceesay held 548,027 shares of common stock directly. Additional shares are held indirectly by The Ceesay Family Irrevocable Trust and The Dorothy Ceesay Irrevocable Trust, for which he disclaims beneficial ownership except to any pecuniary interest.
Rapport Therapeutics, Inc. director John Maraganore received a grant of stock options covering 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036. Following this award, he holds 15,200 options directly.
The options vest upon the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders, subject to his continued service on that vesting date. This is a compensation-related award rather than an open-market purchase or sale.